Inmune Bio Inc. (INMB)
| Market Cap | 152.61M |
| Revenue (ttm) | 10,916 |
| Net Income (ttm) | -14.58M |
| Shares Out | 14.93M |
| EPS (ttm) | -1.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $9.64 |
| Previous Close | $10.06 |
| Change ($) | -0.42 |
| Change (%) | -4.17% |
| Day's Open | 10.20 |
| Day's Range | 9.32 - 10.28 |
| Day's Volume | 162,910 |
| 52-Week Range | 4.50 - 29.99 |
Company to host conference call today, May 5, at 4:30pm ET Company to host conference call today, May 5, at 4:30pm ET
Management to host conference call at 4:30 pm ET on that day Management to host conference call at 4:30 pm ET on that day
LA JOLLA, Calif, April 26, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patie...
Innate Killer Digital Summit 2021, which is being held March 23-25
Company to host conference call today, March 4, at 4:30pm ET Company to host conference call today, March 4, at 4:30pm ET
The wild ride for the biotech stock started with its announcement of results from a phase 1b study.
Interim data show CSF biomarkers of neurodegeneration and synaptic dysfunction as well as neuroimaging biomarkers improved after three months of therapy with XPro1595
Webinar to review expanded biomarker data from the company's Phase 1b clinical trial of XPro1595 targeting neuroinflammation in patients with Alzheimer's disease
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities ...
LA JOLLA, Calif, Nov. 09, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innat...
INmune Bio, Inc. (INMB) CEO RJ Tesi on Q3 2020 Results - Earnings Call Transcript
Management to host conference call at 4:30 pm ET on that day
LA JOLLA, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s inna...
LA JOLLA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patien...
100 patient blinded, randomized, biomarker-directed Phase 2 study will use neuroimaging technology to study the complex biology of treatment resistant disease
LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s i...
LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s in...
INmune Bio Inc. (INMB) CEO RJ Tesi on Q2 2020 Results - Earnings Call Transcript
The company will host an earnings call: Today, August 5 at 4:30 PM ET The company will host an earnings call: Today, August 5 at 4:30 PM ET
LA JOLLA, Calif, July 31, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a pa...
LA JOLLA, Calif, July 27, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s in...
LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, July 20th by INmune Bio, Inc. (NASDAQ: INMB) was incorrectly reported with below sentence:
LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a pat...
LA JOLLA, Calif, July 16, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a...
INmune Bio: Stronger Support From Alzheimer's Drug XPro1595
LA JOLLA, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing treatments that harness...
Inmune Bio (INMB) stock is taking off on Tuesday after announcing positive Alzheimer's news for its leading drug candidate XPro1595.
Inmune Bio stock skyrocketed to a record high Tuesday after the biotech company unveiled promising results for its Alzheimer's treatment. The drug targets inflammation in the brain.
Micro-cap biotech INmune Bio Inc (NASDAQ: INMB) is advancing strongly Tuesday following a positive clinical readout from the company.
XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memory XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memory
Study will be the first-in man trial for INKmune – a novel therapy to prime the patient’s own NK cells to attack their cancer
Review highlights the history, progress and potential of cells of the innate immune system that can be harnessed for treatment of cancer
INmune Bio Inc. (INMB) CEO RJ Tesi on Q1 2020 Results - Earnings Call Transcript
The company will host an earnings call: Today, May 14 at 4:30 PM ET The company will host an earnings call: Today, May 14 at 4:30 PM ET
LA JOLLA, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune syst...
Conference call at 4:15 PM ET with management to discuss the science and strategy of clinical trial to determine if the Company’s DN-TNF platform could be used to treat catastrophic complications of...
INmune Bio Inc. (INMB) CEO R.J.
Grant will fund proof-of-concept studies for XPro1595 therapy
Dr. Malú Tansey's peer-reviewed data from INmune Bio's lead compound XPro1595 published in Alzheimer's Research & Therapy Dr. Malú Tansey's peer-reviewed data from INmune Bio's lead compound XPro1595 pu...
Phase II program to focus on women with trastuzumab resistant HER2+ breast cancer
About INMB
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancer... [Read more...]
| Industry Biotechnology | IPO Date Feb 4, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol INMB |
Analyst Forecasts
According to 4 analysts, the average rating for Inmune Bio stock is "Buy." The 12-month stock price forecast is 29.50, which is an increase of 206.02% from the latest price.